ESR1 and breast carcinoma: We then restricted our analysis to ERα-positive breast cancer patients from the published TCGA data to exploit the more complete clinical annotations [24] and found that 28/364 (8%) carried potential PBX1 amplification/overexpression (Fig. 5A).